In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rory Evans Rory Evans is a writer focused on skin-care and beauty products.

As many of us battle colds, coughs, and the flu during another winter season, a familiar piece of advice is likely to recirculate: Make sure you're loading up on vitamin C. After all, the nutrient has ...

For over a decade, Ruth has written for multiple outlets providing patient education, including Health. She has written for health student education companies, collaborating on an anatomy textbook ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

There’s a solid chance the Audi Concept C is the most important new product out of Ingolstadt in more than two decades. Not so long ago, this “other car brand” from Bavaria was a bit of an automotive ...

Mercedes-Benz doesn’t just have a rival to the second-gen BMW iX, unveiling the new GLC with EQ Technology in Germany, but it is also gearing up to launch an all-electric version of the C-Class to ...

Master the art of crocheting the letter C with this easy-to-follow tutorial! Perfect for beginners and crafters who want to personalize blankets, banners, or gifts. Follow each step to create a neat ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...